Leading a new era in radiopharmaceuticals

Telix is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.

Telix’s deep pipeline for prostate, kidney, brain (glioblastoma), and hematologic cancers, and rare diseases is underpinned by a reliable and secure global supply chain, manufacturing and distribution network.

Telix has received global regulatory approvals from the Australian Therapeutic Goods Administration (TGA), the US Food and Drug Administration (FDA), and Health Canada for its prostate cancer imaging agent and has more than 20 clinical trials underway worldwide.